Supporting Information

Yuen et al. 10.1073/pnas.1010025108

SI Materials and Methods

Electrophysiological Recording in Prefrontal Cortex Slices or Cultures. All experiments were carried out with the approval of State University of New York at Buffalo Animal Care Committee. In brief, animals were anesthetized by inhaling 2-bromo-2-chloro-1,1,1-trifluoroethane (1 mL/100 g; Sigma) and decapitated. Brains were quickly removed and sliced (300–400 μm) with a Leica VT1000S Vibratome while bathed in a hepes-buffered solution (in mM: 132 sodium isethionate, 2 KCl, 4 MgCl₂, 0.1 CaCl₂, 15 hepes, 23 glucose). Slices were then incubated for 1 to 5 h at room temperature (22–24 °C) in artificial cerebrospinal fluid (ACSF) (in mM: 130 NaCl, 26 NaHCO₃, 1 CaCl₂, 5 MgCl₂, 3 KCl, 10 glucose, 1.25 NaH₂PO₄) bubbled with 95% O₂, 5% CO₂. To elevate basal neuronal activity, slices were pretreated with the GABAAR antagonist bicuculline (Bic, 10 μM) for 2 h or an oxygenated low Mg²⁺ ACSF (1 mM MgCl₂) for 2 h. To dampen basal neuronal activity, slices were pretreated with TTX (0.5 μM) for 2 h or the NMDAR antagonist 2-amino-5-phosphonovaleric acid (APV, 25 μM) for 2 h. These reagents were washed off for ~0.5 h before recording, and care was taken to finish recording within ~1.5 h after the pretreatments.

To measure AMPAR-mediated synaptic currents in prefrontal cortex (PFC) slices (1, 2), patch pipettes were filled with the internal solution containing (in mM): 130 Cs-methanesulfonate, 10 CsCl, 4 NaCl, 1 MgCl₂, 10 hepes, 5 EGTA, 2.2 QX-314, 12 phosphocreatine, 5 MgATP, 0.5 Na₂GTP, 0.1 leupeptin, pH 7.2 to 7.3, 265 to 270 mOSM. PFC slices were perfused with oxygenated ACSF. Neurons were observed with a 40× water-immersion lens and illuminated with near infrared light, and the image was captured with an infrared-sensitive CCD camera. Recordings were performed using a Multiclamp 700A amplifier. The evoked NMDAR-EPSC and GABAAR-EPSC traces are the average of 10 trials. The summary data from groups of cells are represented in bar graphs (mean ± SEM). Experiments with different groups were analyzed statistically using one-way ANOVA, followed by post hoc Tukey tests. Miniature synaptic currents were analyzed with Mini Analysis Program (Synaptosoft). Statistical comparisons of mEPSC were made using the Kolmogorov-Smirnov test.

Immunocytochemistry. The procedures were similar to what was previously described (1, 3, 7). PFC cultures (days in vitro 24–28) were either untreated or treated with Bic (10 μM, 2 h) or TTX (0.5 μM, 2 h), and then some were subject to a short PD168077 treatment (40 μM, 10 min). After treatment, neurons were fixed (4% paraformaldehyde, 20 min) and blocked (5% BSA, 1 h). After washing, neurons were permeabilized by Triton (0.2%, 20 min), and incubated with anti-GluR1 (1:500; Millipore) and anti–PSD-95 antibody (1:500; Abcam) or anti-GluR2/3 (1:500; Millipore) and anti-Synaptophysin (1:500; Sigma) at 4 °C overnight. After three washes, neurons were incubated with theAlex594 (red) and Alex488 (green) conjugated secondary antibodies (1:200; Molecular Probe) at room temperature for 1 h. Following three washes, the coverslips were mounted on slides with Vectashield mounting media (Vector Laboratories).

Fluorescent images were captured with a 100× objective and a cooled CCD camera mounted on a Nikon microscope using identical parameters and quantified with the Image J software. To define dendritic clusters, a single threshold was chosen manually, so that clusters corresponded to puncta of two- to threefold greater intensity than the diffuse fluorescence on the dendritic shaft. The threshold for the cluster size was set at 0.03 μm². Three to four independent experiments for each of the treatments were performed. On each coverslip, the cluster density, size, and fluorescence intensity of four to six neurons (two to three dendritic segments of at least 50-μm length per neuron) were compared. Quantitative analyses were conducted blindly.

Biochemical Measurement of Surface-Expressed Receptors. The surface AMPA receptors were detected as previously described (2). Briefly, after treatment, PFC cultures were incubated with ACSF containing 1 mg/mL sulfo-NHS-LS-biotin (Pierce Chemical Co.) for 20 min on ice. The cultures were then rinsed three times in TBS to quench the biotin reaction, followed by homogenization in 300 μL of modified radio-immunoprecipitation assay buffer (1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, 50 mM NaPO₄, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 10 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM PMSF, and 1 mM/mL leupeptin). The homogenates were centrifuged at 14,000 × g for 15 min at 4 °C. To measure total protein, 15 μg of protein were removed. For surface protein, 150 μg of protein were incubated with 100 μL 50% Neuravidin agarose (Pierce Chemical Co.) for 2 h at 4 °C, and bound proteins were re-
suspended in 25 μL of SDS sample buffer and boiled. Quantitative Western blots were performed on both total and biotinylated (surface) proteins using antibody against GluR1 (1: 500; Santa Cruz) and GluR2 (1: 500; Chemicon).

**Western Blotting.** After treatment, equal amounts of protein from PFC culture homogenates (in 1% SDS lysis buffer) were separated on 7.5% acrylamide gels and transferred to nitrocellulose membranes. The blots were blocked with 5% nonfat dry milk (1 h, room temperature), followed by incubation with the anti-CaMKII or anti-p-CaMKII (both 1:1,000; Upstate) for 2 h at room temperature. After three washes, the blots were incubated with a horseradish peroxidase-conjugated secondary antibody (1:1,000; Amersham Biosciences) for 1 h at room temperature. After three washes, the blots were exposed to the enhanced chemiluminescence substrate. Quantification was obtained from densitometric measurements of immunoreactive bands on films.


![Fig. S1.](image)

**Fig. S1.** Excitability and baseline glutamatergic transmission of PFC pyramidal neurons are bidirectionally changed by Bic or TTX pretreatment in a sustained manner. (A) Plot of spike numbers (mean ± SEM) in response to different current injections in PFC slices of either untreated or pretreated with Bic (10 μM, 2 h) or TTX (0.5 μM, 2 h). Recordings were performed after washing off these agents for various durations (0, 30–40 min, 2 h, n = 7 for each group). *P < 0.05, compared with untreated control neurons. (B) Plots showing the averaged (mean ± SEM) amplitude of AMPAR-EPSC in PFC slices with Bic or TTX pretreatment after different time of washing (0–2 h, n = 12–15 for each group). *P < 0.01, compared with untreated control neurons.

![Fig. S2.](image)

**Fig. S2.** The evoked EPSC is mediated by AMPA receptors. (A–C) Plot of eEPSC in representative PFC pyramidal neurons showing its complete blockade by NBQX (10 μM) (A) and its insensitivity to the application of bicuculline (10 μM) (B) or APV (100 μM) (C). (Inset, B and C) Representative eEPSC traces at time points denoted by 1 or 2.
Fig. S3. D₄ receptors induce a long-lasting reduction of the amplitude, but not the paired-pulse ratio, of AMPAR-EPSC in PFC pyramidal neurons. (A and B) Plot of normalized peak AMPAR-EPSC in representative cells showing the effect of PD168077 (40 μM) in the absence or presence of the D₄ antagonist L-741,742 (20 μM). L-741,742 was applied either before (A) or after (B) PD168077 treatment. (C) Bar graphs (mean ± SEM) showing the PPR of AMPAR-EPSC (50-ms interval) before (control) or after PD168077 application in PFC pyramidal neurons from nontreated or Bic-pretreated slices (n = 8 for each group). The group II mGluR agonist APDC (50 μM) was also tested as a positive control for paired-pulse ratio measurement (n = 10). *P < 0.001.

Fig. S4. D₄ receptor knockout blocks the bidirectional effect of D₄ agonist on AMPAR-EPSC. (A–C) Plot of normalized peak AMPAR-EPSC showing the effect of PD168077 (40 μM) in representative PFC pyramidal neurons from WT vs. D₄ KO mice. The slices were either untreated (A) or pretreated with (B) Bic (10 μM) or (C) TTX (0.5 μM) for 2 h. (Inset) Representative eEPSC traces in D₄⁻/⁻ cells before and after PD168077 application (denoted by #). (Scale bars, 50 pA, 10 ms.)
Fig. S5. Activation of D₄ receptors by endogenous dopamine induces an activity-dependent bidirectional regulation of AMPAR-EPSC in PFC pyramidal neurons. (A–C) Plot of normalized peak AMPAR-EPSC in representative cells showing the effect of the dopamine transporter inhibitor GBR-12909 (10 μM, coapplied with sulpiride and SCH23390) in the absence or presence of L-741,742 (10 μM) in PFC pyramidal neurons either untreated (A) or pretreated with (B) Bic (10 μM, 2 h) or (C) TTX (0.5 μM, 2 h). (D) Bar graphs (mean ± SEM) showing the percentage change of AMPAR-EPSC by GBR-12909 (in the presence of sulpiride and SCH23390) in PFC pyramidal neurons with different treatments. **P < 0.05; *P < 0.001.
**Fig. S7.** D₄ bidirectionally regulates AMPAR-EPSC in PFC pyramidal neurons via a mechanism independent of GABA Rs and NMDARs. (A and B) Plot of AMPAR-EPSC showing the effect of PD168077 (40 μM) recorded in the presence of Bic (10 μM, 2 h) or TTX (0.5 μM, 2 h). (Inset) Representative current traces at time points denoted by *. (B) Bar graphs (mean ± SEM) showing the percentage change of AMPAR-EPSC by PD168077 in PFC pyramidal neurons at different activity states. *P < 0.001.

**Fig. S6.** Dopamine D₂ receptors in PFC pyramidal neurons suppress AMPAR-EPSC in an activity-independent manner, and D₄ suppresses AMPAR-EPSC in PFC layer I GABAergic interneurons independently of neuronal activity. (A) Plot of AMPAR-EPSC showing the effect of quinpirole (20 μM) in representative PFC pyramidal neurons from untreated slices or slices pretreated with Bic (10 μM, 2 h) or TTX (0.5 μM, 2 h). (Inset) Representative current traces at time points denoted by *. (B) Bar graphs (mean ± SEM) showing the percentage reduction of AMPAR-EPSC by quinpirole in PFC pyramidal neurons with different treatments. (C–E) Plot of AMPAR-EPSC showing the effect of PD168077 (40 μM) in representative layer I PFC interneurons from untreated slices or slices pretreated with Bic or TTX. (F) Bar graphs (mean ± SEM) showing the percentage reduction of AMPAR-EPSC by PD168077 in layer I PFC interneurons with different treatments.
Fig. S8. CaMKII is involved in the regulation of AMPAR-EPSC by Bic or TTX treatment. (A) Western blots and quantification of p-CaMKII in lysates of PFC slices pretreated with different durations (10 min, 1 h, 2 h) of Bic (10 μM) or TTX (0.5 μM). Blotting was conducted either immediately after treatment or 1 h after washing off (w) Bic or TTX. *P < 0.001. (B) Western blots and quantification showing the effect of PD168077 (40 μM, 10 min) on p-CaMKII in PFC slices pretreated with bicuculline (10 μM, 2 h) or TTX (0.5 μM, 2 h). One hour after washing off Bic or TTX, PD168077 was applied. (C) Cumulative plot of mEPSC amplitudes in representative PFC cultures with or without Bic (10 μM, 2 h) pretreatment in the presence of KN-93 (10 μM, 30 min before Bic). (D) Cumulative plot of mEPSC amplitudes with or without TTX (0.5 μM, 2 h) pretreatment in representative PFC cultures infected with tCaMKII Sindbis virus or treated with the transcription inhibitor Actinmyocin D (50 μM, 30 min before TTX). (Inset, C and D) Representative mEPSC traces. (Scale bars, 50 pA, 1 s.) (E) Bar graphs (mean ± SEM) showing the mEPSC amplitude and frequency in PFC cultures with different pretreatments. *P < 0.001.

Table S1. The basic properties of PFC pyramidal neurons in slices with different treatments

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>+Bic</th>
<th>+TTX</th>
<th>+APV</th>
<th>+Low Mg²⁺</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting potential (mV)</td>
<td>-67.1 ± 1.3</td>
<td>-65.2 ± 1.6</td>
<td>-68.2 ± 1.7</td>
<td>-67.9 ± 2.1</td>
<td>-63.7 ± 1.8</td>
</tr>
<tr>
<td>Input resistance (MΩ)</td>
<td>142.5 ± 17.7</td>
<td>148.3 ± 14.5</td>
<td>138.2 ± 21.8</td>
<td>162.5 ± 24.9</td>
<td>152.6 ± 18.8</td>
</tr>
<tr>
<td>Spike half-width (ms)</td>
<td>2.7 ± 0.3</td>
<td>2.8 ± 0.4</td>
<td>3.1 ± 0.4</td>
<td>2.7 ± 0.5</td>
<td>2.8 ± 0.3</td>
</tr>
<tr>
<td>Spike amplitude (mV)</td>
<td>77.3 ± 2.8</td>
<td>79.2 ± 1.4</td>
<td>61.2 ± 1.7*</td>
<td>78.6 ± 1.8</td>
<td>78.2 ± 2.1</td>
</tr>
<tr>
<td>Spike threshold (mV)</td>
<td>-48.8 ± 1.3</td>
<td>-46.8 ± 0.7</td>
<td>-38.6 ± 1.6*</td>
<td>-49.2 ± 1.8</td>
<td>-47.3 ± 1.5</td>
</tr>
<tr>
<td>Rheobase (pA)</td>
<td>64.3 ± 8.9</td>
<td>42.5 ± 8.0*</td>
<td>108 ± 10.2*</td>
<td>84.6 ± 7.4*</td>
<td>38.3 ± 7.1*</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SEM.

*P < 0.05, ANOVA, compared with control.